PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Thera combines its first atomic-resolution MPER-TMD-CT ...
2026-09-23T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies
BEIJING , Sept. 22, 2026 /PRNewswire/ -- Tsingke today announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed ...
2026-09-22T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader ...
2026-09-22T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
AIMD Expands A-LRYNGO, the World's First AI-Guided Video Laryngoscope, to Global Markets
Dual Korean Government Recognition Advances AI-Guided Intubation Toward a New Standard in Airway Management ...
2026-09-22T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia ...
2026-09-22T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
CHENGDU, China , Sept. 22, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Multiple Phase III clinical studies ...
2026-09-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
NUH ENDOCRINOLOGY TEAM SHOWCASES END-TO-END CARE MODEL THAT PROTECTS HOSPITALISED PATIENTS WITH DIABETES MELLITUS (DM) ACROSS THEIR CARE JOURNEY
NUH's Inpatient DM management team highlights how safe prescribing is strengthened through proactive monitoring, rapid intervention and coordinated care transitions. ...
2026-09-22T    Education   Health Care/Hospital   Medical/Pharmaceuticals 
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
SUZHOU, China , Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision ...
2026-09-22T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
HONG KONG , Sept. 22, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies ...
2026-09-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Red Sea Global and Dr. Sulaiman Al Habib Medical Group Inaugurate The Red Sea Hospital
- The new hospital advances RSG's vision for an integrated healthcare ecosystem across its destinations ...
2026-09-21T    Health Care/Hospital   Hotels and Resorts   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.